Topical Oestrogens and Antimuscarinics In The Treatment Of Detrusor Overactivity

Is There A Synergic Effect Of Topical Oestrogens When Associated To Antimuscarinics In The Treatment Of Symptomatic Detrusor Overactivity

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00648310

Enrollment

Unknown

Registered

2008-04-01

Start date

2004-01-31

Completion date

2007-12-31

Last updated

2008-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive Bladder

Brief summary

Despite the great number of reports about the efficacy of oestrogens or antimuscarinics on OAB symptoms, so far no author has tried to investigate whether the concomitant administration of these two drugs, acting on two different pathophysiological mechanisms, could have a synergic effect reducing the rate of non-responders to treatment.

Interventions

DRUGTolterodine 4 mg

DRUGarm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

* All post-menopausal women with symptoms of overactive bladder and urodynamically proven pure detrusor overactivity

Exclusion criteria

* concomitant urodynamic stress incontinence * documented recurrent urinary tract infections * previous antimuscarinic treatment * previous pelvic surgery * concomitant systemic HRT * history of breast or endometrial cancer * neurological disease * clinical contraindications to treatment with oestrogen or antimuscarinics * patients included in other ongoing clinical trials

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026